In type 2 diabetic patients with mixed dyslipidemia on maximal statin therapy, the addition of the PCSK9 inhibitor alirocumab is more effective than usual care.
In patients with atrial fibrillation on oral anticoagulation, higher ApoA1 levels were associated with a lower risk of stroke, systemic embolism, and all-cause and CV mortality.
In patients with ischemic stroke ≥ 65 years, diabetes is associated with a higher risk of mortality, recurrent events, HF and hospitalisations.
Latest frontiers in anticoagulation therapy Prof. John Eikelboom summarizes results from COMPASS / Hokusai VTE Cancer trials and discusses the implications for clinical practice.
5 Things a cardiologist needs to know about diabetes Prof Naveed Sattar discusses the value of HbA1c to diagnose T2DM, and how HbA1c levels are related to the risk of developing micro and macrovascular disease and the consequences thereof for choosing a HbA1c therapeutic target.
Prof. Libby explains the role of IL-1β in CV disease and the effects of antiinflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab
Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.
In a single-center observational study, less than 50% of acute coronary syndrome patients were on recommended therapies at discharge, which was associated with an increase in 1-year mortality.
Latest frontiers in anticoagulation therapy Prof. John Eikelboom summarizes results from RE-CIRCUIT / RE-DUAL PCI trials and discusses the implications for clinical practice.
In a community-based population without baseline CVD, increasing physical activity over 6 years was associated with reduced HF risk over the next two decades.
Patients with a history of MI and MVD are at increased risk for MACE and coronary events compared to those without MVD and benefit from long-term ticagrelor therapy.
Catheter ablation is associated with a lower mortality and morbidity rate compared to medical therapy in patients with heart failure and atrial fibrillation.